Galectin-1 Inhibition as a Strategy for Malignant Peripheral Nerve Sheath Tumor Treatment
Cells · 2025
DOI: 10.3390/cells14070515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Hsiao-Chi Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Kibio Inc., Houston, TX 77021, USA. Hauptthemen laut MEDLINE: Galectin 1, Nerve Sheath Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, United States Department of Defense.
Abstract (Originalsprache)
Neurofibromatosis type 1 (NF1) is an inherited disorder that predisposes individuals to malignant peripheral nerve sheath tumors (MPNSTs), a highly aggressive sarcoma with limited treatment options and poor prognosis. This study explores the potential of targeting the interaction between Galectin-1 and Ras as a novel therapeutic strategy for MPNSTs. Through molecular docking, we identified critical residues involved in the Galectin-1 and H-Ras interaction. We developed LLS30, a compound designed to target this Ras-binding pocket on Galectin-1, and tested its efficacy. LLS30 effectively disrupted the Galectin-1/Ras interaction, causing Ras delocalization from the plasma membrane and inhibiting Ras signaling. In vitro experiments showed that LLS30 significantly decreased MPNST cell proliferation and induced apoptosis. In vivo, LLS30 demonstrated potent anti-tumor effects, reducing tumor size, inhibiting metastasis, and extending survival in animal models. Transcriptome analysis further revealed the downregulation of KRAS signaling and inhibition of pathways associated with epithelial–mesenchymal transition. These findings suggest that targeting Galectin-1 with LLS30 offers therapeutic potential for MPNSTs and could be beneficial for other cancers driven by Galectin-1 and Ras signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Development, Kibio Inc., Houston, TX 77021, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Biomedical Data Science, Stanford University, Stanford, CA 94304, USA.
- Division of Pediatric Hematology-Oncology, UC Davis Children's Hospital, Sacramento, CA 95816, USA.
- Comprehensive Cancer Center, University of California at Davis, Davis, CA 95616, USA.
- Divisions of Nephrology and Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of California at Davis, Davis, CA 95616, USA.
ORCID-Profile: Ching-Hsien Chen, Tsung-Chieh Shih
Förderung
- NCI NIH HHS
- NIH HHS
- United States Department of Defense
- United States National Institutes of Health
Zitieren
APA
Wang, H. C., Torres, K. E., Xia, R., Malogolowkin, M. H., Hsu, S. W., Chen, C. H., & Shih, T. C. (2025). Galectin-1 Inhibition as a Strategy for Malignant Peripheral Nerve Sheath Tumor Treatment. Cells. https://doi.org/10.3390/cells14070515
Vancouver
Wang HC, Torres KE, Xia R, Malogolowkin MH, Hsu SW, Chen CH, et al. Galectin-1 Inhibition as a Strategy for Malignant Peripheral Nerve Sheath Tumor Treatment. Cells. 2025. doi:10.3390/cells14070515
BibTeX
@article{Wang2025,
author = {Wang, Hsiao-Chi and Torres, Keila E and Xia, Roger and Malogolowkin, Marcio H and Hsu, Ssu-Wei and Chen, Ching-Hsien and Shih, Tsung-Chieh},
title = {Galectin-1 Inhibition as a Strategy for Malignant Peripheral Nerve Sheath Tumor Treatment},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14070515}
}
EUVIMED